Summary
Thirty patients with advanced renal cell carcinoma (RCC), 23 of whom had distant metastases in at least one organ, were entered after nephrectomy into a protocol involving vaccination with Newcastle disease virus (NDV)-modified autologous tumour material, with a subsequent induction week and repetitive bi-weekly cycles of interleukin-2 (rIL-2) and interferon α2b/rIFN-α2b at a lower s. c. dose (1.5 million Cetus units m−2 day−1 every 12 h on 2 days and 3 million IU/m2 once a day on days 1, 3 and 5). The inpatient treatment was followed by a maintenance phase during which 0.3 million Cetus units/m2 rIL-2 was given s. c. every 12 h on days 1–5 and 3 million IU m−2 day−1 rIFN-α2b was administered on days 1, 3, and 5 on an outpatient basis. All but 3 patients completed the induction week and 6 weeks of outpatient therapy. No grade 3 or 4 toxicities occurred during the therapy. Therapy was discontinued for 3 patients because of rapid tumour progression. Of the 23 evaluable RCC patients, 3 exhibited a complete response and 4 displayed partial remission, 7 showed stable disease during 1–18 months (median = 5 months) of therapy, and progression was seen in 9. We conclude that vaccination with autologous tumour material combined with s. c. rIL-2 and rIFN-α2b administration can induce regressions in patients with advanced RCC and that even in non-responding patients a more favourable course of the disease can be achieved.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atzpodien J, Körfer A, Franks CR, Poliwoda H, Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-α-2b in advanced human malignancies. Lancet 335:1509–1512
Aulitzky W, Gastl G, Aulitzky WE, Herold M, Kemmler J, Mull B, Frick J, Huber C (1989) Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon gamma. J Clin Oncol 7:1875–1884
Brown CL, Peters PC, Prager MD, Baechtel S (1981) Specific immunotherapy of metastatic renal cell carcinoma. (Abstract 337) Proc (AUA) Boston
Cassel WA, Murray DR, Phillips H (1983) A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 52:856–860
Fauci AS (1987) Immunomodulators in clinical medicine. Ann Intern Med 106:421–433
Fowler JE (1986) Failure of immunotherapy for metastatic renal cell carcinoma. J Urol 135:22
Galligioni E, Francini M, Carbone A et al. (1989) Specific delayed type cutaneous hypersensitivity (DTCH) to autologous tumor in renal cancer patients treated with active specific immunotherapy (ASI). (Abstract 690) Proc Am Soc Clin Oncol 8:178
Hanna MG, Hoover HC, Peters LC et al. (1987) Fundamental and applied aspects of successful active specific immunotherapy of cancer. In: Oldham R (ed) Cancer biotherapy, principles and practice. Raven Press, New York, pp 195–221
Heicappell R, Schirrmacher V, Hoegen P von, Ahlert T, Appelhans B (1986) Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumour cells: I. Parameters for optimal therapeutic effects. Int J Cancer 37:569–577
Hollinshead A, Stewart THM, Takita H, Dalvow M, Concannon J (1987) Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens. Cancer 60:1249–1262
Hoover HC, Surdyke MG, Dangel RB (1985) Prospectively randomized trial of adjuvant active specific immunotherapy for human colorectal cancer. Cancer 55:1236–1243
Hoover HC, Surdyke MG, Brandhorst JS (1990) Five-year follow-up of a controlled trial of active specific immunotherapy in colorectal cancer. Proc Am Soc Clin Oncol 9:106
Kemmner W, Schlag P, Brossmer R (1987) A rapid and simple procedure for dissociation of tumour tissue from the human colon. J Cancer Res Clin Oncol 113:400–401
Kurth KH, Marquet R, Zwartendij KJ, Warmaar SO (1987) Autologous anticancer antigen preparation for specific immunotherapy in advanced renal cell carcinoma. Eur Urol 13:103–109
McCune CS, Marquis DM (1990) Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res 50:1212–1215
McCune CS, Schapira DV, Henshaw EC (1981) Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 47:1984–1987
Meuer SC, Dumann H, Buschenfelde KM et al. (1989) Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15–17
Mitchell MS, Kempf RA, Harel W et al. (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated malignant melanoma. J Clin Oncol 6:409–424
Negrier S, Philip T, Stoter G et al. (1989) Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol 25:21–28
Neidhardt JA, Murphy SG, Hennick LA, Wise HA (1980) Active specific immunotherapy of stage for renal carcinoma with aggregated tumour antigen adjuvant. Cancer 46:1128–1134
Numberg JH, Doyled MV, York SM et al. (1989) Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci USA 86:4240–4243
O'Donnell RW, Marquis RW, Mudholkar GS, McCune CS (1986) In vivo enhancement of antitumour immunity by interleukin 2-rich lymphokines. Cancer Res 46:3273–3278
Otto U, Schneider AW, Conrad S, Klosterhalfen H (1990) Combined therapy with TNF- and -2a interferon. J Urol 143:292A
Pomer S, Thiele R, Staehler G (1989) Die Behandlung des fortgeschrittenen Nierenzellkarzinoms mittels kombinierter Vakzinierung mit modifiziertem autologem Tumormaterial und Interleukin-2. Methodencharakterisierung und vorläufige Ergebnisse. In: Hofstetter A, Staehler G, Kriegmair M, Schuth J (eds) Zytokine in der urologischen Onkologie. Akt Onkol 57:28–37
Pomer S, Thiele R, Schirrmacher V, Staehler G (1989) Augmentation of DTH reactivity to active specific immunotherapy by local application of IL-2 in patients with renal cell carcinoma. Nat Immun Cell Growth Regul 9:66
Rosenberg SA, Lotze MT, Muul LM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:880–897
Sahasrabudhe DM, de Kernion JB, Pontes JE et al. (1986) Specific immunotherapy with suppressor function inhibition in metastatic renal cell carcinoma. J Biol Response Mod 5:581–594
Schärfe T, Becht E, Klippel KF, Jacobi GH, Hohenfellner R (1986) Active immunotherapy of stage IV renal cell cancer using autologous tumour cells. Wld J Urol 3:245–248
Schirrmacher V, Heicappell R (1987) Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumour cells. II. Establishment of specific systemic anti tumour immunity. Clin Exp Metastasis 5:147–156
Tallberg T, Tykkä H (1986) Specific active immunotherapy in advanced renal cell carcinoma. A clinical longterm follow-up study. Wld J Urol 3:234–244
Weinberg A, Merigan TC (1988) Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. J Immunol 140:294–299
West WH, Tauer KW, Yannelli JR (1987) Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pomer, S., Thiele, R., Daniel, V. et al. Sequential treatment of patients with advanced renal cell carcinoma with autologous tumor vaccine and subcutaneous administration of recombinant interleukin-2 and interferon α2b . World J Urol 9, 223–227 (1991). https://doi.org/10.1007/BF00182845
Issue Date:
DOI: https://doi.org/10.1007/BF00182845